Arvinas’ $16.2M Revenue Won’t Cover Its $55M Loss

Forward-Looking Analysis

Analyst consensus projects Arvinas to report Q2 2026 revenue of $16.2 million, reflecting a modest increase from prior periods driven by ongoing collaboration payments and initial licensing activity. Net income estimates remain deeply negative, with consensus forecasts pointing to a loss of approximately $55.0 million, as the company continues to prioritize clinical development expenditures over immediate profitability. Earnings per share (EPS) are expected to land at -$0.85, an improvement from the previous quarter’s -$0.90, indicating slight operational efficiency gains or reduced burn rates. Major financial institutions maintain a cautious stance, with 59% of 17 analyst ratings classified as Buy, while 35.3% advise a Sell. Price targets currently cluster around the $8.50 mark, suggesting limited upside from current trading levels of $7.42. No significant upgrades or downgrades have been issued recently, maintaining a neutral-to-slightly-positive sentiment among 58.8% of analysts who hold the stock. These projections rely strictly on existing pipeline valuations and the anticipated commercialization timeline for VEPPANU, with no speculative growth assumptions included in these baseline figures.

Historical Performance Review

Arvinas delivered Q1 2026 results with revenue of $15.60 million, matching its gross profit of $15.60 million, indicating zero cost of goods sold typical for clinical-stage biotechs. The company reported a net loss of $57.60 million, resulting in an EPS of -$0.90. This performance reflects continued heavy investment in R&D and operational expenses while awaiting key regulatory milestones.

Additional News

On May 1, 2026, the FDA granted approval for VEPPANU (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer, marking a pivotal regulatory milestone for Arvinas. This approval follows a collaboration with Pfizer, under which Arvinas shares worldwide development costs, commercialization expenses, and profits, though they have jointly agreed to seek a third-party partner for commercialization. In March 2026, Arvinas announced positive Phase 1 data for ARV-102, an oral PROTAC LRRK2 degrader, showing greater than 50% LRRK2 degradation in the cerebrospinal fluid of Parkinson’s disease patients after 28 days of treatment. Arvinas presented this data at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders. Corporate leadership changes include the February 2026 appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director. Additionally, Arvinas reported its Fourth Quarter and Full Year 2025 financial results in February 2026, providing updates on its pipeline and corporate strategy.

Summary & Outlook

Arvinas maintains a precarious financial health profile, characterized by persistent net losses and negative EPS, though Q1 showed stable revenue generation. The primary growth catalyst is the recent FDA approval of VEPPANU, which opens commercialization opportunities despite the ongoing search for a third-party partner. Risks remain elevated due to heavy cash burn and the binary nature of clinical trials for pipeline assets like ARV-102. While the PROTAC platform offers a unique technological advantage in addressing undruggable targets, the company’s near-term prospects are neutral. Investors should monitor VEPPANU commercial execution and ARV-102 Phase 2 data closely. Until revenue streams from approved therapies scale significantly to offset R&D costs, the outlook remains cautious, balancing high-potential innovation against sustained financial losses.